{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}],"title":"Baseline Negative, Negative post-baseline"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline Negative, Positive post-baseline"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Baseline Positive, Negative post-baseline"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Baseline Positive, Positive post-baseline"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Number of participants with ATA were reported.","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS population with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"From first dose until 9.33 months","title":"Number of Participants With Antitherapeutic Antibodies (ATA)","type":"SECONDARY","unitOfMeasure":"Participants"}